Evidence-based medicine in cystic fibrosis: how should practice change?
This critical review of current practice and research in some aspects of cystic fibrosis (CF) concludes that, despite recent success in prolonging life expectancy, there is still room for improvement in terms of earlier diagnosis and earlier intervention in some of its complications. Specifically, the body of evidence implies that neonatal diagnosis; early attention to nutrition, staphylococcal and pseudomonal infection, and diabetes mellitus; and early treatment with dornase alfa can all be expected to improve patients' quality and quantity of life.
Conway
Steven P
SP
Department of Pediatrics, St. James's and Seacroft Hospitals, Leeds, United Kingdom.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001827:Body Height; D001835:Body Weight; D003550:Cystic Fibrosis / Q000150:complications / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy*; D003850:Deoxyribonuclease I / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000209:etiology; D019317:Evidence-Based Medicine; D006801:Humans; D009747:Nutritional Physiological Phenomena; D011552:Pseudomonas Infections / Q000150:complications; D011994:Recombinant Proteins / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D011994:Recombinant Proteins; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I